Red Light Therapy for Prostate Cancer: What the Evidence Shows

TL;DR

• Prostate cancer is the most commonly diagnosed cancer in Australian men, an estimated 28,868 new cases in 2025, but five-year survival for localised disease is now 96%. Treatment side effects (erectile dysfunction, urinary incontinence, fatigue) significantly impact quality of life across often-years of survivorship.
• Photodynamic therapy (PDT) with vascular-targeted photosensitisers activated by laser fibres is the most researched light-based intervention for prostate cancer. Padeliporfin (TOOKAD) PDT achieved negative biopsy in 68–80% of treated areas in Phase II trials and significantly better cancer control than active surveillance in Phase III trials.
• Standalone photobiomodulation, the mechanism in consumer red light therapy devices, works through entirely different pathways. It does not use a photosensitising agent and cannot destroy tumour tissue. Its relevance to prostate cancer is as a potential adjuvant support tool for treatment side effects: inflammation, fatigue, pain, and tissue recovery.
• WALT guidelines consider photobiomodulation safe for cancer-bearing patients but advise against direct application over known tumour sites. Do not use red light therapy devices over the prostate area without oncologist approval.
• Red light therapy is not a prostate cancer treatment. Any use during active treatment or survivorship must be discussed with your oncologist or urologist first.

Prostate cancer is the most commonly diagnosed cancer in Australian men, approximately 28,868 new cases estimated in 2025, yet five-year survival has risen from 60% in the late 1980s to 96% today for localised disease. That means a growing number of Australian men are living with and beyond prostate cancer, managing treatment side effects across years of survivorship.

Light-based therapies appear frequently in prostate cancer conversations, but the landscape is more nuanced than a simple headline suggests. Clinical photodynamic therapy, using photosensitising agents activated by laser light, is a genuine and increasingly validated treatment for early localised prostate cancer. Standalone photobiomodulation (the mechanism in consumer red light therapy devices) operates through entirely different mechanisms and has a different relevance: as a potential adjuvant support tool for treatment side effects, not a cancer treatment. This guide covers both clearly, with appropriate safety context for men navigating prostate cancer.

Understanding Prostate Cancer and Its Treatment Landscape

The prostate is a walnut-sized gland in the male reproductive system. Prostate cancer develops when cells grow abnormally, most are adenocarcinomas, and many grow slowly enough that active surveillance is appropriate for low-risk disease. PSA blood testing and biopsy confirm diagnosis and grading (Gleason scoring). Treatment options span radical prostatectomy, radiotherapy (external beam or brachytherapy), and androgen deprivation therapy (ADT) for advanced disease. Each carries a distinctive side effect profile: prostatectomy risks urinary incontinence and erectile dysfunction; radiotherapy risks proctitis and urinary symptoms; ADT causes hot flushes, loss of libido, bone density loss, and fatigue. Managing these side effects, and supporting quality of life across often-years of treatment, is where adjuvant approaches including photobiomodulation become relevant.

How Light Therapy Relates to Prostate Cancer

Photodynamic Therapy: The Clinical Approach

Clinical photodynamic therapy for prostate cancer uses a photosensitising agent, administered intravenously, that concentrates in tumour vasculature. When activated by laser light delivered via optical fibres inserted through the perineum into the prostate under general or regional anaesthesia, the photosensitiser generates reactive oxygen species that destroy the blood vessels supplying the tumour, causing localised ischaemic necrosis. This vascular-targeted mechanism allows focal ablation of tumour-bearing areas while preserving surrounding healthy tissue. PDT for prostate cancer is a clinical procedure requiring specialist equipment and surgical expertise. It is not replicated by using a home LED panel.

Standalone Photobiomodulation: A Different Mechanism

Standalone photobiomodulation, the mechanism in consumer red and near-infrared light therapy devices, does not use a photosensitising agent and does not generate reactive oxygen species in the same way as PDT. Instead, red and near-infrared wavelengths are absorbed by mitochondria in tissue cells, activating cytochrome c oxidase and increasing ATP production. The downstream effects include reduced pro-inflammatory cytokines, nitric oxide-mediated vasodilation, increased fibroblast proliferation and collagen synthesis, and neural pain signal modulation. These are non-destructive, non-ablative mechanisms that support cellular health rather than destroying tumour tissue. The two approaches are not interchangeable.

What the Research Shows

Vascular-Targeted PDT: Phase II and III Evidence

The most extensively studied PDT approach uses TOOKAD (padeliporfin, WST11), a water-soluble vascular-targeted photosensitiser. A pooled analysis of three Phase II trials involving 117 men with low-risk localised prostate cancer demonstrated negative biopsy in 68.4% of treated lobes at 6 months, rising to 80.6% in the per-protocol subgroup. Mean MRI-confirmed necrosis at day 7 was 76.5%. Side effects were predominantly mild to moderate: dysuria (33%), erectile dysfunction (16%), perineal pain (15%), and haematuria (14%), with all serious adverse events resolving without lasting harm. The Phase III trial (CLIN1001 PCM301, Lancet Oncology 2017) compared vascular-targeted PDT to active surveillance in 413 men with low-risk prostate cancer, finding significantly lower rates of progression to radical treatment (6% vs 29%) and histological progression at 24 months.

Standalone PBM and Cancer Patients: The Evidence Position

The World Association for Laser Therapy (WALT) considers photobiomodulation safe for use in cancer patients. Its most established oncology application is managing oral mucositis from head and neck cancer radiotherapy and chemotherapy, where PBM is now recognised as effective. WALT advises against direct PBM application over known tumour sites but does not consider systemic or distant use a contraindication. No clinical evidence exists specifically testing photobiomodulation for prostate cancer management, prostatectomy recovery, or radiotherapy side effects in prostate populations.

The Honest Evidence Position

Clinical PDT (vascular-targeted, with photosensitising agents and transperineal laser fibres) has Level I evidence from Phase III randomised trial data for localised low-risk prostate cancer. Standalone photobiomodulation has no prostate cancer-specific clinical evidence and is not a prostate cancer treatment. Its anti-inflammatory, wound-healing, and analgesic mechanisms are theoretically relevant to treatment side effect management, but this has not been clinically tested in prostate populations. Men with a prostate cancer diagnosis should not use any light therapy device without discussing it with their oncologist or urologist first.

Safety Considerations for Men With Prostate Cancer

The primary concern with photobiomodulation in cancer patients is theoretical: light at therapeutic doses might stimulate metabolic activity in cancer cells if applied directly over tumour tissue. The WALT panel reviewed the evidence and concluded PBM is safe for systemic use in cancer-bearing patients, but advises against direct application over known tumour sites. This evidence basis is largely in vitro rather than clinical.

For men with prostate cancer: do not apply red light therapy devices over the perineal or lower abdominal area overlying the prostate gland without explicit guidance from your treating specialist, particularly during radiotherapy, when local tissue dynamics are altered. Men who have completed treatment should still discuss any new complementary therapy with their GP, urologist, or oncologist before starting.

Red light therapy should never be used as an alternative to or reason to delay evidence-based prostate cancer treatment.

How to Use Red Light Therapy During Prostate Cancer Survivorship

• Get clearance from your oncologist or urologist first. No complementary therapy should be started during or after prostate cancer treatment without medical sign-off.
• Do not apply directly over the prostate area (lower abdomen, perineum) without explicit medical guidance, in line with WALT safety recommendations.
• Appropriate applications during survivorship include general fatigue and systemic inflammation, joint and muscle pain from androgen deprivation therapy, wound healing support after prostatectomy (over healed tissue only), and wellbeing support.
• Red + NIR combination mode (660nm + 850nm) for anti-inflammatory and tissue recovery support. Sessions of 10–20 minutes, three to five times per week.
• Continue all prescribed medications. Red light therapy is an adjuvant support tool, not a substitute for hormone therapy, ongoing monitoring, or any prescribed component of your care plan.
• Report new symptoms to your care team. Any changes in urinary function, pain, or other concerns during survivorship should be reported to your specialist regardless of complementary therapies in use.

StreamShop Devices for Survivorship Support

LED Light Therapy Dome With 1064nm ($399.99)

StreamShop's LED light therapy dome with 1064nm delivers 660nm, 850nm, and 1064nm across 240 triple-chip LEDs at 87.4 mW/cm². The arch format positions the panel above the treatment area without direct contact and provides hands-free, full-body coverage, practical for managing systemic fatigue and muscle discomfort associated with androgen deprivation therapy.

SS100 Red Light Panel With 1060nm ($749.99)

StreamShop's SS100 red light panel with 1060nm delivers 9 wavelengths at 160 mW/cm² or greater through 72 dual-chip LEDs. ARTG listed with per-wavelength dimming and pulse frequency control (1–10,000Hz). Well suited for targeted treatment of joints, muscle groups, or surgical recovery sites in prostate cancer survivors managing ADT side effects or post-prostatectomy recovery. Not for use directed toward the prostate area without oncologist guidance.

Red Light Therapy Mat With Near-Infrared ($949.99)

StreamShop's red light therapy mat with near-infrared delivers 660nm and 850nm across 1,280 triple-chip LED beads over a full 180cm body surface. For men managing systemic fatigue, bone discomfort, and muscle loss from long-term androgen deprivation therapy, the mat provides full-body photobiomodulation coverage in a single reclining session.

Frequently Asked Questions

Can Red Light Therapy Treat Prostate Cancer?

No. Standalone red light therapy (photobiomodulation without a photosensitising agent) is not a prostate cancer treatment and has no clinical evidence supporting it as one. Clinical photodynamic therapy using vascular-targeted photosensitisers activated by transperineal laser fibres is a separately validated clinical procedure for localised prostate cancer, performed by urologists in hospital settings. Consumer red light therapy devices do not replicate this mechanism and should not be used as a cancer treatment or to delay medical care.

What Is Vascular-Targeted PDT for Prostate Cancer?

Vascular-targeted PDT uses a photosensitising agent (padeliporfin/TOOKAD) given intravenously that concentrates in tumour blood vessels. A urologist activates it with laser light delivered through optical fibres placed transurethrally under anaesthesia. The photosensitiser generates reactive oxygen species that destroy tumour vasculature. Phase III trial data (Lancet Oncology, 2017) showed significantly better cancer control than active surveillance in men with low-risk localised prostate cancer, with lower rates of progression to radical treatment at 24 months.

Is Red Light Therapy Safe for Men With Prostate Cancer?

WALT guidelines consider photobiomodulation safe for cancer-bearing patients based on available evidence, but advise against direct application over known tumour sites. Men with active prostate cancer should not use red light therapy devices over the prostate region without explicit oncologist approval. Men who have completed curative treatment should still discuss any complementary therapy with their care team before starting.

Can Red Light Therapy Help With Prostate Cancer Treatment Side Effects?

Photobiomodulation has strong evidence for managing oral mucositis in cancer radiotherapy patients, its strongest oncology application — and has documented anti-inflammatory, analgesic, and tissue-healing mechanisms. These are theoretically relevant to ADT-related joint and muscle discomfort, post-prostatectomy recovery (over healed tissue), radiation-related inflammation, and cancer-related fatigue. No prostate cancer-specific PBM clinical trials exist. Any use should be discussed with the treating medical team first.

Can Red Light Therapy Help With Prostate Enlargement (BPH)?

BPH is a non-cancerous prostate enlargement causing urinary symptoms, a distinct condition from prostate cancer. There is no established clinical evidence for consumer red light therapy devices improving BPH symptoms. Surgical laser procedures (photoselective vaporisation) are used clinically for BPH but are entirely different from consumer photobiomodulation devices. Men with urinary symptoms should see a GP or urologist for assessment.

What Should I Do If I Have Prostate Cancer and Want to Try Red Light Therapy?

Speak to your oncologist or urologist first. Explain that you are considering a consumer photobiomodulation device, where you intend to use it, and what treatment or surveillance phase you are in. Your specialist can advise on whether it is appropriate, whether any body areas should be avoided, and how it fits within your overall care plan. Never use any complementary therapy as a substitute for prescribed oncological care or PSA monitoring.